68Ga-DOTATATE ( DrugBank: 68Ga-DOTATATE, Dotatate )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 75 | クッシング病 | 1 |
| 84 | サルコイドーシス | 1 |
| 238 | ビタミンＤ抵抗性くる病/骨軟化症 | 1 |
75. クッシング病
臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02019706 (ClinicalTrials.gov) | February 12, 2014 | 21/12/2013 | Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome | Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome | ACTH;Cushing's Syndrome | Radiation: DOTATATE PET-CT;Radiation: F-DOPA PET CT;Radiation: CT scan;Diagnostic Test: Routine MRI scan;Diagnostic Test: Gated MRI scan;Drug: 68Ga-DOTATATE;Drug: 18F-DOPA | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 18 Years | 80 Years | All | 80 | Phase 2 | United States |
84. サルコイドーシス
臨床試験数 : 149 / 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03549598 (ClinicalTrials.gov) | July 20, 2018 | 25/5/2018 | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scan | Mayo Clinic | NULL | Completed | 18 Years | N/A | All | 15 | Phase 4 | United States |
238. ビタミンＤ抵抗性くる病/骨軟化症
臨床試験数 : 29 / 薬物数 : 25 - (DrugBank : 11) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03736564 (ClinicalTrials.gov) | January 31, 2019 | 30/10/2018 | Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia | 68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia | Osteomalacia | Combination Product: 68Ga-DOTATATE PET/CT | Mayo Clinic | NULL | Recruiting | 18 Years | N/A | All | 10 | Phase 1/Phase 2 | United States |